What's New
Front Page
Linde Jacobs Shares Her Families FTD Journey with the New York Times
A recent article in The New York Times highlights the inspiring story of Linde Jacobs, a nurse…
Empower a Future Free of FTD with a Year-End Gift
For over 20 years, AFTD’s volunteers, supporters, and partners raised awareness, supported one another, educated healthcare professionals,…
AFTD Research Team: A Year in Review
2024 has been a hopeful year for FTD Research, and it’s also been an exciting year for…
Article Lists Ways Researchers Can Involve People with Dementia in Identifying Research Priorities
A research article published in the Journal of the American Geriatrics Society discusses how researchers can better…
Perspectives in FTD Research Webinar: FTD Research 2024 – Where We’ve Come From and Where We’re Headed
The science of FTD is evolving at a rapid pace and it can be difficult to interpret…
AFTD Ambassador Advocates on Behalf of the Older Americans Act
AFTD Ambassador Judy Bearer advocated for the reauthorization of the Older Americans Act (OAA) in a December…
Advancing Hope: AFTD Attends 2024 Society for Neuroscience Meeting
Dr. Nicole Bjorklund, AFTD Director of Research and Grants, and Dr. Kate Still, Research Outreach Manager, attended…
New York Software Company Awards AFTD Gift to Honor Employee’s Late Cousin
AFTD has been selected as one of three organizations to receive a gift from Mindex, a software-development…
Transposon Presents Results from Successful Phase 2 ALS/FTD Clinical Trial
Biotechnology company Transposon Therapeutics presented the results from its successful phase 2 clinical trial of its experimental…
AviadoBio CEO Emphasizes Collaborative Approach for Treating FTD
In October, U.K.-based gene therapy company AviadoBio, Ltd., and pharmaceutical company Astellas announced an exclusive option and…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)